[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"opioid-use\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:opioid-use":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,80,0,25,[9,46,69,84,112,130,158,182,209,230,256,280,303,325,351,374,398,422,444,474,511,540,564,585,613],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100369773","hip-arthroscopy-postoperative-opioid-demands-100369773",false,"NCT04094701","Hip Arthroscopy Postoperative Opioid Demands","Randomized Control Trial Evaluating Postoperative Opioid Demands Following Hip Arthroscopy","Inclusion Criteria:\n\n* Adult patients age 18-80 years\n* English speaking\n* Opioid naive patient (defined as not taking opioid pills within 6 weeks prior to surgery), confirmed by checking the Illinois Prescription monitoring program\n* Primary hip arthroscopy\n* Written and informed consent for study participation\n\nExclusion Criteria:\n\n* Minors (\\\u003C18 years of age)\n* Opioid tolerant patients\n* Revision surgery\n* Prior infections of the operative joint\n* History of active malignancy within the past 5 years\n* Chronic pain conditions including low back pain, chronic pain syndrome, fibromyalgia\n* History of alcohol or other substance use disorder\n* Other disease states including rheumatologic conditions, diabetes mellitus, hypo\u002Fhyperthyroidism, depression, anxiety\n* Grade IV chondral defects",true,"ALL","18 Years","80 Years",{"count":22,"type":23},170,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study will be a prospective, single-blinded, randomized controlled trial (RCT), investigating the influence of the number of opioid pills prescribed following primary hip arthroscopy. All patients who sign the consent form will be enrolled in the suited and randomized to one of the two treatment arms. The intervention group will receive 5 Norco pills, gabapentin (30 mg, once daily for 10 days following surgery), and Tylenol (1000 mg, three times daily for 10 days following surgery) while the control will receive the standard at our practice of 30 Norco pills.",[29,30,31,32],"Opioid Use","Pain","Femoral Acetabular Impingement","Labral Tear, Glenoid","RECRUITING","2026-08-11",{"date":36,"type":37},"2026-08-13","ACTUAL",{"date":39,"type":37},"2020-10-21",{"date":41,"type":23},"2028-03",{"name":43,"class":44},"Rush University Medical Center","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":24,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100650993","healing-after-injury-to-reduce-opioid-use-and-pain-through-preventive-engagement---open-trial-100650993","NCT07755527","Healing After Injury to Reduce Opioid Use and Pain Through Preventive Engagement - Open Trial","An Adaptive Psychological Intervention to Improve Pain and Reduce Opioid Use Following an Injury","HOPE","Inclusion Criteria:\n\n* Admitted to Henry Ford Hospital\n* Has an acute musculoskeletal injury\n* Prescribed opioids during the admission\n\nExclusion Criteria:\n\n* Under age 18\n* Cognitive impairment (i.e., diagnosis of delirium, dementia, or traumatic brain injury\u002FGlasgow Coma Scale less than 13)\n* Chronic pain condition (i.e., pain most of the day, nearly every day for the past 3 months or longer)\n* Taking opioids 30 days or more prior to this hospitalization",{"count":55,"type":23},10,[26],"The goal of this project is to refine the adaptive psychological intervention and assess initial feasibility and acceptability. Results will be used to inform a pilot randomized trial.",[30,29],"NOT_YET_RECRUITING","2026-08-05",{"date":62,"type":37},"2026-08-10",{"date":64,"type":23},"2026-09",{"date":66,"type":23},"2027-03",{"name":68,"class":44},"Henry Ford Health System",{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":24,"phases":75,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":78,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":4},"100649964","healing-after-injury-to-reduce-opioid-use-and-pain-through-preventive-engagement-100649964","NCT07741201","Healing After Injury to Reduce Opioid Use and Pain Through Preventive Engagement",{"count":5,"type":23},[26],"The goal of this proposed project is to optimize the adaptive psychological intervention and assess the feasibility and acceptability. The long-term objective of this line of research is to evaluate whether an adaptive psychological intervention delivered after a musculoskeletal injury is effective in preventing the development of chronic pain and long-term opioid use.",[30,29],{"date":62,"type":37},{"date":80,"type":23},"2027-03-01",{"date":82,"type":23},"2028-05-31",{"name":68,"class":44},{"id":85,"slug":86,"hasResults":12,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":12,"sex":92,"minAge":19,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":24,"phases":96,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":45},"100644956","spsip-block-versus-esp-block-for-chronic-pain-after-unilateral-breast-surgery-100644956","NCT07674836","SPSIP Block Versus ESP Block for Chronic Pain After Unilateral Breast Surgery","Comparison of Serratus Posterior Superior Intercostal Plane Block and Erector Spinae Plane Block for the Prevention of Chronic Postoperative Pain After Unilateral Breast Surgery: A Prospective, Randomized, Assessor-Blinded Trial","SPES-CPSP","Inclusion Criteria:\n\n* Female patients aged 18-65 years\n* ASA physical status I-III\n* Body mass index (BMI) between 18 and 35 kg\u002Fm²\n* Scheduled for elective unilateral breast surgery (mastectomy with or without sentinel lymph node biopsy)\n* Ability to understand and provide written informed consent\n\nExclusion Criteria:\n\n* Infection at the site of block application\n* Known allergy to local anesthetics\n* Coagulopathy or anticoagulant therapy\n* Chronic opioid use\n* Pregnancy\n* Inability to communicate or cooperate\n* Refusal to participate\n* Failed block\n* Requirement of additional intraoperative analgesia outside the study protocol\n* Development of serious intraoperative complications","FEMALE","65 Years",{"count":95,"type":23},90,[26],"This prospective, randomized, assessor-blinded study will compare serratus posterior superior intercostal plane block and erector spinae plane block in adult female patients undergoing unilateral breast surgery. The primary outcome is chronic postoperative pain at 3 months, assessed using the Brief Pain Inventory-Short Form.",[99,29],"Postoperative Pain",[101,29],"Post Operative Pain","2026-08-04",{"date":104,"type":37},"2026-08-06",{"date":106,"type":37},"2026-07-01",{"date":108,"type":23},"2026-12-01",{"name":110,"class":111},"Engin Çetin","OTHER_GOV",{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":12,"sex":92,"minAge":19,"maxAge":93,"enrollmentInfo":118,"targetDuration":4,"studyType":24,"phases":120,"briefSummary":121,"conditions":122,"keywords":123,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":124,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":45},"100634542","serratus-vs-esp-block-for-postoperative-pain-in-unilateral-breast-surgery-100634542","NCT07541040","Serratus vs ESP Block for Postoperative Pain in Unilateral Breast Surgery","Comparison of Serratus Posterior Superior Intercostal Plane Block and Erector Spinae Plane Block for Postoperative Analgesia in Unilateral Breast Surgery: A Prospective, Randomized, Assessor-Blinded Trial",{"count":119,"type":23},54,[26],"This prospective, randomized, assessor-blinded trial compares serratus posterior superior intercostal plane block (SPSIPB) and erector spinae plane block (ESPB) for postoperative analgesia in unilateral breast surgery. 54 patients will be randomized to receive either SPSIPB or ESPB before general anesthesia.\n\nThe primary outcome is postoperative pain scores within the first 24 hours. The secondary outcome is opioid consumption.",[101,29],[101,29],{"date":104,"type":37},{"date":126,"type":37},"2026-05-01",{"date":128,"type":23},"2026-09-01",{"name":110,"class":111},{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":140,"phases":4,"briefSummary":141,"conditions":142,"keywords":147,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":157},"100566142","fmri-and-opioid-abstinence-100566142","NCT06651333","fMRI and Opioid Abstinence","Functional Connectivity Mechanisms of Opioid Abstinence","Inclusion Criteria:\n\n* recent initiation of methadone or buprenorphine at a clinic, program, or doctor within the past year (i.e., period of time during which treatment drop-out and risk for relapse is highest);\n* eligibility for MRI scanning;\n* ability to commit to study visits.\n\nExclusion Criteria:\n\n* current acute psychosis, mania, or suicidal ideation with intent, as assessed during screening with the SCID-5;\n* current intoxication or acute withdrawal at time of study visit sufficient to prevent participation based on: behavioral observation, breathalyzer, and SOWS assessment;\n* severe cognitive impairment as determined via trained clinical research staff through consent process and during consent quiz or as indicated by a PROMIS Cognitive Function tscore \\\u003C30 (i.e., severe impairment)\n* past or present history of intellectual disability, developmental disorder, or neurological disease;\n* head trauma with loss of consciousness \\>30 min;\n* organ dysfunction or any unstable or untreated medical conditions that may interfere with study participation.","50 Years",{"count":139,"type":23},240,"OBSERVATIONAL","This project examines functional connectivity patterns associated with subsequent relapse to illicit opioids during treatment for OUD.",[143,144,145,29,146],"Drug Use Disorder","Opioid Dependence","Opioid-Related Disorders","Opioid Abuse",[148],"Relapse",{"date":150,"type":37},"2026-08-07",{"date":152,"type":37},"2024-12-12",{"date":154,"type":23},"2029-11",{"name":156,"class":44},"Yale University",2,{"id":159,"slug":160,"hasResults":12,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":164,"enrollmentInfo":165,"targetDuration":4,"studyType":24,"phases":167,"briefSummary":169,"conditions":170,"keywords":173,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":178,"leadSponsor":180,"locationsCount":45},"100609743","phase-1-evaluation-of-the-safety-and-effects-of-psychoactive-substances-in-people-with-past-opioid-use-100609743","NCT07218549","Evaluation of the Safety and Effects of Psychoactive Substances in People With Past Opioid Use","Inclusion Criteria:\n\n1. English-speaking, 18- to 55-year-old males or females.\n2. Female subjects must have a negative serum pregnancy test at time of screening and negative urine pregnancy test upon admission. In addition, female subjects must meet one of the following conditions:\n\n   * Is a woman of non-childbearing potential defined as no menses for at least 12 months with status confirmed by FSH and estradiol levels at screening or surgically sterile at screening visit OR\n   * Is a woman of childbearing potential and using a contraceptive method that is highly effective, with a failure rate of \\\u003C1%, from Screening until 9 months after receiving the study medication. The investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated) in relationship to the dose of study intervention.\n3. Male subjects must agree to the following from Day 1 until 9 months after receiving the study medication:\n\n   • Not donate fresh unwashed semen\n\n   Plus, either:\n   * Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR\n   * Use a male condom and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak when having sexual intercourse with a woman of childbearing potential who is not currently pregnant.\n   * Use a male condom when engaging in any activity that allows for passage of ejaculate to another person\n4. Physically healthy, as determined by a clinical interview with a physician, laboratory tests (urinalysis, blood chemistry, 12-lead ECG), physical examination, and self-reported medical history.\n5. No current or past diagnosis of severe mental illness, as determined by a clinical interview.\n6. Clinical laboratory test results (CMP, CBC, etc.) must be within the normal reference range or with acceptable deviations that are judged to be not clinically significant by a study physician.\n7. Have a history of self-reported recreational opioid use as defined by at least 10 times in the past year and at least once in the 12 weeks before screening.\n8. Able and willing to give signed informed consent, reliable, and willing to make themselves available for the study's duration and follow study procedures.\n9. Agree not to consume any recreational drugs during the study (THC is excluded).\n10. Able to perform study procedures as determined by clinical judgment.\n11. Able to meet eligibility requirements of the Qualification Phase (i.e., drug discrimination) and Naloxone Challenges.\n\nExclusion Criteria:\n\n1. Seeking treatment for a substance or alcohol use disorder as determined by self-report during the intake interview.\n2. Current or past diagnosis of opioid use disorder or other substance use disorder (SUD) within the past year, excluding THC and nicotine-containing products. With regard to marijuana\u002FTHC, an individual must be able to tolerate 48 hours of abstinence from marijuana\u002FTHC products.\n3. History of opioid overdose.\n4. Using medication or supplements that might interact with kratom or oxycodone as determined by self-report during intake interview.\n5. Treatment with any investigational drug during the last 30 days.\n6. Participants on parole or probation.\n7. Currently pregnant or trying to conceive or currently lactating as determined by blood pregnancy testing at screening, urine pregnancy testing at admission, and self-reporting during interview and study visits.\n8. Current or recent history of significant violent or suicidal behavior or suicidal\u002Fhomicidal risk as determined by the C-SSRS.\n9. Sensitivity, allergy, or contraindications\u002Fallergies to kratom, opioids, or similar compounds.\n10. Use prescription or nonprescription drugs and dietary supplements within seven days or five half-lives (whichever is longer) that, in the opinion of the study clinician may interfere with the investigational product.\n11. Positive urine drug screen (UDS) for substances of abuse at each admission in the Qualification and Treatment phases, excluding tetrahydrocannabinol (THC). If a participant presents with a positive UDS excluding THC at any admission or any visit, the investigator, at their discretion, may reschedule a repeat of UDS until the UDS is negative, excluding THC, before the participant is permitted to participate in any phase of the study.\n12. Positive alcohol breathalyzer test at each admission in the Qualification and Treatment Phase.\n13. History of sensitivity to heparin or heparin-induced thrombocytopenia.\n14. Has not donated blood or plasma within the last six weeks.\n15. Has a history of increased intracranial pressure or brain tumors.\n16. Has gastrointestinal obstruction, including paralytic ileus.\n17. Has a history of seizure disorders.\n18. Has a chronic obstructive pulmonary disease or cor pulmonale.\n19. Has a history of anemia or any other significant hematologic disorder.\n20. Has a condition or abnormality that, in the opinion of the PI or Study Physician, would compromise the safety of the patient or the quality of the data.\n21. Has a major surgery planned within the next 6 months.","55 Years",{"count":166,"type":23},72,[168],"PHASE1","The purpose of this study is to understand how kratom affects people. In this study, kratom will be compared with another substance and a placebo (an inactive substance). Researchers will also study how the substances move through and affect the body. This includes examining how the body absorbs, processes, and eliminates the drug (pharmacokinetics), as well as how the drug affects the body and how it may make you feel (pharmacodynamics). The information collected will help researchers better understand the effects and potential risks of kratom.",[29,171,172],"Substance Use Disorders","Opioid Analgesia",[29,171],"2026-07-28",{"date":176,"type":37},"2026-07-30",{"date":128,"type":23},{"date":179,"type":23},"2029-05-31",{"name":181,"class":44},"Christopher D. Verrico",{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":24,"phases":192,"briefSummary":193,"conditions":194,"keywords":198,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":45},"100601002","autonomic-neural-blockade-in-bariatric-surgery-100601002","NCT07104825","Autonomic Neural Blockade in Bariatric Surgery","Autonomic Neural Blockade During Sleeve Gastrectomy and Gastric Bypass: A Randomized Controlled Trial Evaluating Pain and Nausea After Bariatric Surgery","Inclusion Criteria:\n\n* Individuals able and willing to consent and participate in all study activities\n* Adults, ages 18-90\n* All patients with severe obesity undergoing laparoscopic\u002Frobotic gastric bypass or sleeve gastrectomy\n\nExclusion Criteria:\n\n* Patients taking opiates chronically\n* Patients allergic to study medications\n* Patients with any prior adverse reaction to ingredients included in the block\n* Adults unable to consent\n* Pregnant women\n* Prisoners","90 Years",{"count":191,"type":23},200,[26],"The purpose of this research is to evaluate if autonomic nerve block (ANB- blocking pain and nausea signals) decreases pain and anti-nausea medication requirements as well as the experience of pain\u002Fnausea during the first 72 hours after sleeve gastrectomy or gastric bypass surgery. Participants will be randomly assigned either to the standard of care or the ANB group before surgery. As part of standard of care, in both groups, laparoscopic bariatric surgery will be initiated with local anesthetic injected into the abdominal wall. In the ANB group, participants will be given an additional injection of local anesthetic medication to block nerves on and around the stomach.",[195,196,197,29],"Bariatric Surgery Candidate","Pain, Postoperative","Nausea and Vomiting, Postoperative",[199],"Autonomic, blockade, bariatric surgery","2026-07-27",{"date":202,"type":37},"2026-07-29",{"date":204,"type":37},"2026-02-05",{"date":206,"type":23},"2027-12",{"name":208,"class":44},"Endeavor Health",{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":93,"enrollmentInfo":216,"targetDuration":4,"studyType":24,"phases":218,"briefSummary":219,"conditions":220,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":157},"100485923","neural-mechanisms-of-meditation-for-opioid-treated-chronic-low-back-pain-100485923","NCT05607381","Neural Mechanisms of Meditation for Opioid-Treated Chronic Low Back Pain","Neural Mechanisms of Meditation-Based Interventions for Chronic Low Back Pain","Inclusion Criteria:\n\n1\\) men\u002Fwomen 18-65 years of age; 2) current chronic low back pain classified according to the NIH Pain Consortium task force research standards for chronic low back pain (pain on at least half the days in the past 6 months); usual back pain ≥3 on 0-10 scale with opioid medication; and 4) current use of prescription opioids for ≥3 months.\n\nExclusion Criteria:\n\n1\\) Prior experience with MBSR, MBCT, MORE, or extensive involvement in any standardized meditation training, 2) current cancer diagnosis, 3) suicide intent or attempt in the past 30 days, 4) psychosis or moderate\u002Fsevere non-opioid substance use disorder in past 6 months; 5) persons with any electronic objects or certain metal objects in their head or body that are incompatible with MRI; 6) those who have had an abnormal brain MRI in the past; 7) those unable to lie still on their back for 1 to 1.5 hours; and 8) pregnancy.",{"count":217,"type":23},188,[26],"The purpose of this research study is to see how a mindfulness meditation-based intervention affects pain. Specifically, we are interested in understanding the pain-relieving brain mechanisms of mindfulness meditation-based therapy for patients with opioid-treated chronic low back pain.",[221,29],"Low Back Pain","2026-07-23",{"date":200,"type":37},{"date":225,"type":37},"2022-11-30",{"date":227,"type":23},"2027-06-30",{"name":229,"class":44},"University of Utah",{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":12,"sex":238,"minAge":19,"maxAge":4,"enrollmentInfo":239,"targetDuration":4,"studyType":24,"phases":241,"briefSummary":243,"conditions":244,"keywords":246,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":249,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":45},"100423791","phase-2-pain-alleviation-with-testosterone-in-opioid-induced-hypogonadism-100423791","NCT04798469","Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism","Androgen Replacement to Improve Patient-Important Outcomes in Men With Opioid-Induced Hypogonadism","PATH","Inclusion Criteria:\n\n* Men, age 18 years and older.\n* Chronic non-cancer spinal pain.\n* Use of opioid analgesics for at least 6 months.\n* Serum total testosterone (measured by mass spectrometry) \\\u003C348 ng\u002FdL and\u002For free testosterone \\\u003C70 pg\u002FmL.\n* Ability and willingness to provide informed consent.\n\nExclusion Criteria:\n\n* History of prostate cancer or breast cancer.\n* Known history of organic hypogonadism (e.g., due to hypothalamic, pituitary or testicular disease).\n* Use of testosterone within the past 6 months.\n* Baseline hematocrit \\>48%.\n* Prostate-specific antigen (PSA) level \\>4 ng\u002FmL in Caucasians or \\>3 ng\u002FmL in African-Americans.\n* Presence of prostate nodule or induration on digital rectal examination.\n* Uncontrolled congestive heart failure.\n* Myocardial infarction, acute coronary syndrome, revascularization surgery or stroke within 3 months.\n* Serum creatinine \\>2.5 mg\u002FdL.\n* Alanine aminotransferase (ALT) level 3 times above the upper limit of normal.\n* Diagnosis of bipolar disorder or schizophrenia.\n* Presence of metallic implants (pacemakers, aneurysm clips, etc.) that preclude the patient from undergoing functional magnetic resonance imaging (MRI). In subjects who are otherwise eligible and either do not qualify for MRI or are reluctant to undergo imaging, the investigators may consider enrolling such participants on a case-by-case basis.","MALE",{"count":240,"type":23},150,[242],"PHASE2","The aim of this trial is to evaluate whether testosterone replacement results in greater improvement in pain perception, pain tolerance, sexual function, fatigue, and quality of life when compared with placebo in men with chronic spinal pain treated with opioids who have opioid-induced hypogonadism (low testosterone).",[29,30,245],"Hypogonadism, Male",[30,247,248],"Opioid Analgesics","Testosterone",{"date":200,"type":37},{"date":251,"type":37},"2022-01-10",{"date":253,"type":23},"2027-12-30",{"name":255,"class":44},"Brigham and Women's Hospital",{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":263,"targetDuration":4,"studyType":24,"phases":265,"briefSummary":267,"conditions":268,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":157},"100518673","phase-3-motivational-interviewing-and-mindfulness-oriented-recovery-enhancement-100518673","NCT06033599","Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement","Motivational Interviewing (MI) and Mindfulness-Oriented Recovery Enhancement (MORE) for Tobacco Dependence and Other Drug Use in Methadone Treatment","Inclusion Criteria:\n\n* English-speaking\n* Age ≥18\n* Currently on methadone; and 4) currently smoke cigarettes.\n\nExclusion Criteria:\n\n* Severe cognitive impairment (score \\>23 on Mini Mental Status Exam) or psychosis (positive SCID Psychotic Screen)\n* Suicidal risk (score ≥7 on Suicidal Behaviors Questionnaire)\n* Inability to attend or fully participate in intervention sessions or assessments\n* Previous formal mindfulness training (e.g., MBSR, MBRP) or MORE (from the R21 or R33\n* Currently taking smoking cessation pharmacotherapy or participating in smoking cessation counseling\n* Any contraindications for NRT\n* Currently or soon planning to be pregnant or breastfeeding.",{"count":264,"type":23},420,[266],"PHASE3","The purpose of this study is to 1) examine barriers and facilitators to implementation of MI and MORE for polysubstance use and evaluate strategies for optimizing training, fidelity, and clinic uptake, and 2) evaluate patient outcomes related to the effectiveness of MORE decreasing opioid, tobacco, and other drug use.",[269,29,270],"Polysubstance Abuse","Tobacco Use","2026-07-15",{"date":273,"type":37},"2026-07-17",{"date":275,"type":37},"2023-09-05",{"date":277,"type":23},"2028-08",{"name":279,"class":44},"Rutgers, The State University of New Jersey",{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":92,"minAge":288,"maxAge":289,"enrollmentInfo":290,"targetDuration":4,"studyType":140,"phases":4,"briefSummary":292,"conditions":293,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":45},"100517875","sex-hormones-postoperative-pain-and-opioid-use-100517875","NCT06023225","Sex Hormones, Postoperative Pain and Opioid Use","Relationship Between Sex Hormones, Postoperative Pain and Opioid Use: the Role of Immune Factors","SPO","Inclusion Criteria:\n\nPediatric female patients between the ages 11-16 undergoing an orthopedic (trauma and non-trauma) surgical procedure involving a long bone or joint, or the spine, English speaking\n\nExclusion Criteria:\n\nPregnancy; Diagnosis of chronic pain, Psychiatric, developmental or neurological disorders, Disorders that are associated with pubertal maturation (e.g., precocious puberty).","11 Years","16 Years",{"count":291,"type":23},210,"Aim 1- To identify relationships between sex hormone levels and postoperative pain and opioid use.\n\nAim 2: To determine whether the effects of testosterone on postoperative pain and opioid use are mediated by immune factors",[99,29],"2026-07-10",{"date":296,"type":37},"2026-07-13",{"date":298,"type":37},"2023-09-01",{"date":300,"type":23},"2029-07-01",{"name":302,"class":44},"Washington University School of Medicine",{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":310,"enrollmentInfo":311,"targetDuration":4,"studyType":24,"phases":313,"briefSummary":314,"conditions":315,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":45},"100484265","opioid-dispensing-device-for-post-operative-pain-in-cancer-patients-100484265","NCT05585788","Opioid Dispensing Device for Post-Operative Pain in Cancer Patients","Efficacy of a Pill-Dispensing System to Increase Disposal of Unused Opioids and to Reduce Refills After Cancer-Related Surgery","Inclusion Criteria:\n\n* Adult patients (age greater than or equal to 18 years)\n* Planned for major cancer-related surgery and expected to receive a postoperative opioid prescription\n* Must speak English or Spanish\n* Must have access to a smartphone or an alternative smart device (e.g., iPhone, Android phone, iPad, Surface, etc.).\n* Co-enrollment in trials involving pharmacologic therapy is allowed\n\nExclusion Criteria:\n\n* Patients who are taking opioids daily prior to the surgical procedure\n* Patients unable to physically utilize the device\n* Patients unable to self-administer medications\n* Patients uncomfortable with using iPhone or iPad-based technology","99 Years",{"count":312,"type":23},140,[26],"This research study will evaluate the use of, and participants experience with, a new device called Addinex that safely stores and dispenses opioid medication. The purpose of this study is to evaluate the use of the Addinex device in cancer patients undergoing cancer-related surgery that require pain control with opioids after the surgery. Participants will be asked to answer questions about their medical history and background, fill out questionnaires, use a mobile application associated with the device, and undergo a phone interview one month after stopping use of the device. This study aims to find out how participants like using the Addinex device as opposed to a traditional pill bottle. Results of this study will help determine if the Addinex device could be useful to patients in the future after surgeries, as opposed to typical pill bottles.",[29,316],"Breast Cancer","2026-07-09",{"date":294,"type":37},{"date":320,"type":37},"2020-10-05",{"date":322,"type":23},"2027-07",{"name":324,"class":44},"Columbia University",{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":4,"eligibilityCriteria":331,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":332,"targetDuration":4,"studyType":24,"phases":334,"briefSummary":335,"conditions":336,"keywords":340,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":45},"100591497","phase-2-effects-of-lemborexant-on-insomnia-and-its-relationship-to-mood-and-behavior-on-opioid-use-disorder-subjects-100591497","NCT06981195","Effects of Lemborexant on Insomnia and Its Relationship to Mood and Behavior on Opioid Use Disorder Subjects","Neurofunctional Phenotyping to Investigate the Role of the Orexin System at the Intersection of Opioid Use Disorder and Insomnia Among Women and Men Receiving Buprenorphine","Inclusion Criteria:\n\n1. Be 18 + years-of-age\n2. Meet current DSM-5 criteria for opioid use disorder (OUD) with at least moderate severity\n3. Receiving outpatient treatment for OUD with sublingual buprenorphine film\u002Ftablets ranging 8mg to 24mg or with extended-release injectable buprenorphine\n4. Stabilized on current buprenorphine dosage for at least 4 weeks without intention for dose change within next 3 months.\n5. Screening urine toxicology positive for buprenorphine and an appropriate norbuprenorphine level as determined by a study clinician\n6. A screening urine toxicology negative for non-prescribed substances (except cannabinoids) with a negative breath (or oral fluid) alcohol screen\n7. Screen positive for chronic insomnia on the Insomnia Symptom Questionnaire (ISQ)\n8. Have an Insomnia Severity Index score at screening and baseline of 13 or higher\n9. Have no clinically significant medical or psychiatric disorder or condition, based on physical exam and medical history performed by study clinician, that in the judgement of the investigator would prevent participation or heighten safety risks\n10. Understand the study procedures and provide written informed consent in English language\n11. Access to necessary resources for completing virtual surveys and monitoring (i.e., computer or smartphone, internet or cell service)\n\nExclusion Criteria:\n\n1. Current diagnosis of sleep-related breathing disorder, narcolepsy, somnambulism, or sleep paralysis\n2. A positive screen for sleep apnea by the following: Sleep Disorders Screening Battery (STOP-BAG \\>5) OR home sleep apnea test using WatchPAT with Apnea Hypopnea Index (AHI) with 3% drop in oxygen saturation \\> 10 OR \\>50% of respiratory events being central if AHI is between 5-10 OR Oxygen Desaturation \\\u003C 88% for \\> 10 minutes, OR oxygen desaturation index (ODI) using 3% drop in oxygen saturation \\> 10\n3. Currently receiving treatment for insomnia (behavioral or pharmacologic)\n4. Currently taking a medication to treat a sleep-related condition (e.g., zolpidem) or unable to discontinue over-the-counter drug or supplement used to treat sleep-related condition\n5. Currently taking benzodiazepines or other CNS active medications that may increase risk to the participant, per PI discretion (e.g., opioids other than buprenorphine, antipsychotics)\n6. Current DSM-5 diagnosis (any severity) of alcohol or drug use disorder (e.g., benzodiazepine, stimulant) with non-prescribed substance use within last 3 months; nicotine use disorder is not considered exclusionary\n7. Cannabis use \\> 3 days\u002Fweek\n8. Uncontrolled serious psychiatric disorder that would make study participation unsafe (such as Bipolar I Disorder, ADHD, Schizophrenia, schizoaffective disorders, major depressive disorder with psychotic features, or a neurological disorder).\n9. Uncontrolled neurological, cardiovascular, or pulmonary medical condition such as seizure disorder, recent myocardial infarction, stroke, hospitalization for chronic obstructive pulmonary disease\n10. Baseline ECG with clinically significant abnormal conduction or with QTc of greater than 450ms\n11. Significant current suicidal or homicidal ideation (C-SSRS \"yes\" answers on questions 4 or 5) or a history of suicide attempt within the past 6 months\n12. Any of the following lab abnormalities: ALT\u002FAST 2 or more times the upper limit of normal, Total bilirubin 2 or more times the upper limit of normal, Creatinine 1.5 or more times the upper limit of normal\n13. Pregnant or breastfeeding; Females who are having sex that includes penile penetration must be non-pregnant, non-lactating, and either be of non-childbearing potential (e.g., sterilized via hysterectomy, bilateral tubal ligation, or bilateral oophorectomy, or at least 1 year post-menopausal) or of childbearing potential, and agree to use an acceptable form of contraception (e.g., IUD, hormonal implant, hormonal patch\u002Fring\u002Fpill, condoms (male or female), etc.)\n14. Currently taking prescription or over-the counter drugs or dietary supplements known to significantly inhibit CYP3A4 (such as clarithromycin, telithromycin, nefazodone, itraconazole, ketoconazole, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, tipranavir); or CYP3A4 inducers (such as phenobarbital, phenytoin, rifampicin, St. John's Wort, and glucocorticoids)\n15. Currently taking lemborexant or any previous medically adverse reaction to lemborexant or other dual orexin receptor antagonists\n16. Currently incarcerated or pending incarceration",{"count":333,"type":23},100,[242],"The goal of this clinical trial is to learn about how certain medications used to treat insomnia (e.g., Lemborexant) impact sleep, mood, and behavior in men and women with Opioid Use Disorder who are taking prescribed buprenorphine. The main questions it aims to answer are:\n\n1. What is the effect of the study drug (lemborexant) on sleep outcomes?\n2. What is the effect of the study drug (lemborexant) on impulsive behavior (as measured by computer test performance)?\n3. What is the effect of the study drug (lemborexant) on mood and other behavior?\n\nResearchers will compare lemborexant to placebo (e.g., sugar pill) to see if participants assigned to 8 weeks of treatment with lemborexant have greater improvements on the measures listed above.\n\nParticipants will take the study medication (or placebo) each night for 8 weeks and be asked to come for a total of 23 study visits. Most of these visits will be very short (15-30 minutes). The longer visits will include the screening visit (about 2-3 hrs), baseline visit (about 2.5 hrs), and the post-medication visit (about 2 hrs). Study visits will include things like taking surveys about sleep, drug use, and mood, completing urine drug testing, checking vital signs (e.g., blood pressure), and completing interviews with the study staff. Participants will also be asked to provide two blood samples (one during screening and one after taking the medication). For three two-week periods, participants will be asked to wear a watch to track sleep at home, and to keep a log of sleep and wake times.",[337,29,338,339],"Opioid Use Disorder","Insomnia","Orexin Antagonist",[341,342],"buprenorphine","lemborexant","2026-07-08",{"date":317,"type":37},{"date":346,"type":37},"2025-05-27",{"date":348,"type":23},"2029-07-30",{"name":350,"class":44},"Virginia Commonwealth University",{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":18,"minAge":358,"maxAge":19,"enrollmentInfo":359,"targetDuration":4,"studyType":24,"phases":361,"briefSummary":362,"conditions":363,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":45},"100548387","ql-vs-lai-for-palatoplasty-100548387","NCT06420336","QL vs LAI for Palatoplasty","Quadratus Lumborum Block for Pain Control in Unilateral Anterior Iliac Bone Graft Harvesting for Pediatric Patients Undergoing Palatoplasty: a Prospective Randomized Control Trial","Inclusion Criteria\n\n* Patients undergoing palatoplasty with autologous bone graft from the anterior iliac crest.\n* Ages 6-18 years of age\n* Planned admission post-op\n* ASA Status Range: 1-3\n\nExclusion Criteria\n\n* Contraindication to QL blocks or LAI which may include:\n* overlying infection skin at the block needle insertion site\n* coagulopathies\n* known bleeding disorders\n* Allergy to local anesthetic\n* Cognitive or developmental impairment that would limit ability to report pain.\n* Non-English Speaking\u002FWriting\n* Subjects or their parent\u002Fguardian unable or choose to not give informed consent\u002Fassent.","6 Years",{"count":360,"type":23},46,[26],"This study will consist of patients ages 6-18 who are undergoing a surgery on the hard or soft palate of the mouth (palatoplasty), with removal of bone from the front of the hip (anterior iliac bone graft harvesting). The patients will be randomized to receive either a unilateral QL block by an anesthesiologist, or local anesthetic infiltration at the surgical incision by the surgeon. The primary aim will be assessing post-operative pain in the first 48 hours after surgery. Secondary outcomes will include pain medication use in the first 48 hours after surgery, block resolution time, and evaluating any complications associated with the QL block or local anesthetic infiltration.",[364,29,365],"Post-operative Pain","Cleft Palate","2026-07-07",{"date":317,"type":37},{"date":369,"type":37},"2024-06-25",{"date":371,"type":23},"2027-01-31",{"name":373,"class":44},"Medical University of South Carolina",{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":382,"enrollmentInfo":383,"targetDuration":4,"studyType":24,"phases":384,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":45},"100484569","phase-1-sleep-disordered-breathing-with-opioid-use-100484569","NCT05589753","Sleep Disordered Breathing With Opioid Use","Targeting Chemoreceptor Control of Breathing During Sleep to Mitigate Opioid-Associated Sleep Disordered Breathing","SDB","Inclusion Criteria:\n\n* Veterans, age 18-89 years\n* Veterans with prescription opioids\n\nExclusion Criteria:\n\n* Patients with BMI\\>40kg\u002Fm2 will be excluded to avoid the effects of morbid obesity on pulmonary mechanics and ventilatory control\n* Patients with history of unresolved\u002Funtreated cardiac disease, including recent myocardial infarction, recent bypass surgery, untreated atrial and ventricular tachy-bradycardias\n* Congestive heart failure with Cheyne-Stokes respiration (CSR)\n* Current unstable angina\n* Recent stroke\n* Untreated schizophrenia\n* Untreated hypothyroidism\n* Unresolved seizure disorder\n* Severe respiratory, neurological, liver and renal diseases\n* Unstable psychiatric disorders\u002Funtreated PTSD\n* Traumatic brain injury\n* Pregnant women\n* Significant sleep disorder such as narcolepsy, parasomnias disorder\n* Failure to give informed consent\n* Patients on tramadol and suboxone\u002Fbuprenorphine","89 Years",{"count":240,"type":23},[168,242],"There is an increased risk for sleep disordered breathing (SDB), sleep-related hypoventilation and irregular breathing in individuals on chronic prescription opioid medications. Almost 30% of a veteran sleep clinic population had opioid-associated central sleep apnea (CSA). The proposal aims to identity whether oxygen and acetazolamide can be effective in reducing unstable breathing and eliminating sleep apnea in chronic opioid use via different mechanisms. We will study additional clinical parameters like quality of life, sleep and pain in patients with and without opioid use. This proposal will enhance the investigators' understanding of the pathways that contribute to the development of sleep apnea with opioid use. The investigators expect that the results obtained from this study will positively impact the health of Veterans by identifying new treatment modalities for sleep apnea.",[387,29,388],"Sleep Apnea","Sleep Disordered Breathing","2026-06-29",{"date":106,"type":37},{"date":392,"type":37},"2019-05-02",{"date":394,"type":23},"2027-03-31",{"name":396,"class":397},"VA Office of Research and Development","FED",{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":24,"phases":407,"briefSummary":408,"conditions":409,"keywords":412,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":45},"100644752","phase-2-leveraging-mhealth-to-promote-opioid-use-recovery-and-mental-health-among-residents-of-a-medium-sized-midwestern-city-100644752","NCT07673380","Leveraging mHealth to Promote Opioid Use Recovery and Mental Health Among Residents of a Medium-Sized Midwestern City","Leveraging mHealth to Promote Recovery From Opioid Use Disorder and Commonly Occurring Mental Health Disorders Among Residents of a Medium-Sized Midwestern City","Inclusion Criteria:\n\n* Have a history of opioid and\u002For stimulant use\n* Identify as Black and\u002For African American\n* Seek treatment at local substance use treatment centers\n* Fluent in English\n* U.S. resident\n* 18 years of age or older at the time of data collection.\n\nExclusion Criteria:\n\n* Self-reported cognitive impairment that would limit ability to participate in research.",{"count":406,"type":23},300,[242],"The sequential trial compares recovery and mHealth engagement outcomes among Black participants who participated in the mHealth intervention uMAT-R or uMAT-R + enhanced community engagement. The mHealth intervention seeks to support people in various stages of recovery who are also seeking other forms of substance use treatment. Participants are recruited from community-based substance use treatment facilities and recovery services. Participants must be adults who have or are currently using opioids and\u002For stimulants.",[29,410,411],"Stimulant Use","Depression and Anxiety Symptoms",[413,414],"Digital health","Community engagement","2026-06-22",{"date":389,"type":37},{"date":418,"type":37},"2025-08-31",{"date":420,"type":23},"2027-02-28",{"name":302,"class":44},{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":428,"enrollmentInfo":429,"targetDuration":4,"studyType":24,"phases":431,"briefSummary":432,"conditions":433,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":45},"100644386","targeting-alcohol-opioid-co-use-among-young-adults-using-a-novel-mhealth-intervention-100644386","NCT07663448","Targeting Alcohol-Opioid Co-Use Among Young Adults Using a Novel MHealth Intervention","Inclusion Criteria:\n\n1. Ages 18 to 25 years, inclusive\n2. Self-report interest in reducing their alcohol-opioid co-use - outside a research study, people who do not wish to change their co-use are unlikely to download and use an mHealth app designed to reduce co-use. It is important to recruit participants who most closely resemble the intended users of the eventual mHealth intervention. This is defined as reporting any alcohol-opioid co-use goal (i.e., not selecting \"No goal\" in response to the alcohol-opioid co-use goal question at the screening visit).\n3. Self-report engaging in simultaneous alcohol-opioid co-use (i.e., use of both substances within two hours) ≥ 1 day\u002Fweek on average in the past 28 days (i.e., at least 4 co-use events in the past 28 days). This requirement will ensure that we observe sufficient use episodes where the pharmacological effects of alcohol and opioids overlap to evaluate project aims.\n4. Able to understand written and oral instructions in English, communicate understanding of the consent form, and provide written informed consent.\n5. Complete all assessments required at screening.\n6. Agree to the schedule of visits, verbally acknowledge that he\u002Fshe\u002Fthey will be able to attend each scheduled visit, participate in phone visits and that he\u002Fshe\u002Fthey does not have any already scheduled events or a job that may substantially interfere with study participation.\n7. Own a smartphone with data plan. Almost all participants (98%) in our preliminary work owned a smartphone with data plan.\n8. Currently reside in the United States of America.\n\nExclusion Criteria:\n\n1. Pregnant or nursing\n2. Current suicidality\n3. History of psychosis","25 Years",{"count":430,"type":23},30,[26],"The goal of this treatment development project is to develop and pilot an adaptive mobile health (mHealth) intervention that targets the co-use of alcohol and opioids in young adults.",[434,29],"Alcohol Drinking","2026-06-17",{"date":437,"type":37},"2026-06-23",{"date":439,"type":37},"2026-06-08",{"date":441,"type":23},"2027-04-30",{"name":443,"class":44},"Brown University",{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":448,"acronym":449,"eligibilityCriteria":450,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":451,"targetDuration":4,"studyType":24,"phases":453,"briefSummary":454,"conditions":455,"keywords":458,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":45},"100578043","machine-learning-prediction-and-reducing-overdoses-with-ehr-nudges-100578043","NCT06806163","Machine-Learning Prediction and Reducing Overdoses With EHR Nudges","mPROVEN","Inclusion Criteria:\n\n* Received an opioid prescription within the past year\n* Age 18 years or older at the time of the opioid prescription\n* At least one visit to an internal medicine or family care practice within the past year\n\nExclusion Criteria:\n\n* Diagnosis of malignant cancer within the past year\n* Enrollment in hospice care",{"count":452,"type":23},1350,[26],"The goal of this cluster randomized clinical trial is to test a clinician-targeted behavioral nudge intervention in the Electronic Health Record (EHR) for patients who are identified by a machine-learning based risk prediction model as having an elevated risk for an opioid overdose.\n\nThe clinical trial will evaluate the effectiveness of providing a flag in the EHR to identify individuals at elevated risk with and without behavioral nudges\u002Fbest practice alerts (BPAs) as compared to usual care by primary care clinicians.\n\nThe primary goals of the study are to improve opioid prescribing safety and reduce overdose risk.",[456,29,337,457],"Opioid Overdose","Opioids",[459,460,461,462,463,464,465,456,457],"Machine learning","Risk prediction","Behavioral nudge","Best Practice Alert","Artificial intelligence","Primary care","Electronic Health Record Platforms","2026-06-16",{"date":435,"type":37},{"date":469,"type":37},"2025-03-10",{"date":471,"type":23},"2027-02",{"name":473,"class":44},"University of Pittsburgh",{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":18,"minAge":481,"maxAge":482,"enrollmentInfo":483,"targetDuration":4,"studyType":24,"phases":485,"briefSummary":487,"conditions":488,"keywords":495,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":45},"100431190","phase-4-opioid-free-anesthesia-analgesia-strategy-and-surgical-stress-in-elective-open-abdominal-aortic-aneurysm-repair-100431190","NCT04894864","Opioid Free Anesthesia-Analgesia Strategy and Surgical Stress in Elective Open Abdominal Aortic Aneurysm Repair","Effect of a Perioperative Opioid Free Anesthesia-Analgesia (OFA-A) Strategy on Surgical Stress Response in Elective Open Abdominal Aortic Aneurysm Repair: A Prospective Randomized Study","Inclusion Criteria:\n\n1. Patient Consent\n2. Age between 40 and 85 years old\n3. Patients undergoing Elective Open Abdominal Aortic Infrarenal Aneurysm Repair\n\nExclusion Criteria:\n\n1. Immunocompromised patients\n2. Patients with active infection\n3. Reoperation on the aorta\n4. Inflammatory bowel Disease\n5. Malignancy\n6. Chronic Inflammatory conditions (e.g. Rheymatoid arthritis, Psoriatic arthritis)\n7. Chronic corticosteroid or immunosuppressive drug use\n8. Intraoperative transfusion with \\>2 units of packed Red Blood Cells","40 Years","85 Years",{"count":484,"type":23},40,[486],"PHASE4","Open Abdominal Aortic Aneurysm (AAA) repair is a high-risk surgical procedure accompanied by intense endocrine and metabolic responses to surgical stress, with subsequent activation of the inflammatory cascade, cytokine and acute-phase protein release, and bone marrow activation. There is a proven correlation of surgical stress, which patients undergoing open AAA repair are subjected to, with patient outcome, morbidity\u002Fmortality, intensive care unit stay and overall length of stay. Modern general anesthetic techniques have been revised and rely on perioperative multimodal anesthetic and analgesic strategies for improved overall patient outcome. Based on this context of a multimodal anesthetic technique and having taken into consideration the international \"opioid-crisis\" epidemic, an Opioid Free Anesthesia-Analgesia (OFA-A) strategy started to emerge. It is based on the administration of a variety of anesthetic\u002Fanalgesic agents with different mechanisms of action, including immunomodulating and anti-inflammatory effects.\n\nOur basic hypothesis is that the implementation of a perioperative multimodal OFA-A strategy, involving the administration of pregabalin, ketamine, dexmedetomidine, lidocaine, dexamethasone, dexketoprofen, paracetamol and magnesium sulphate, will lead to attenuation of surgical stress response compared to a conventional Opioid-Based Anesthesia-Analgesia (OBA-A) strategy. Furthermore, the anticipated attenuation of the inflammatory response, is pressumed to be associated with equal or improved analgesia, compared to a perioperative OBA-A technique.",[489,99,490,29,491,492,493,494],"Elective Surgical Procedures","Anesthesia","Abdominal Aortic Aneurysm Without Rupture","Vascular Surgical Procedure","Interleukin 6","Immunomodulators",[496,497,498,499,500,501,502],"Opioid-free Anesthesia-Analgesia","Cytokines","Opioid-based Anesthesia-Analgesia","Haemodynamic Stability","Open Abdominal Aortic Aneurysm Repair","Immunomodulation","Inflammatory Markers","2026-06-13",{"date":466,"type":37},{"date":506,"type":37},"2020-10-08",{"date":508,"type":23},"2027-09-01",{"name":510,"class":44},"University of Crete",{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":517,"eligibilityCriteria":518,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":519,"targetDuration":4,"studyType":24,"phases":521,"briefSummary":522,"conditions":523,"keywords":526,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":538,"locationsCount":45},"100619275","better-experiences-in-substance-treatment-a-brief-alcohol-focused-intervention-tailored-for-patients-in-opioid-agonist-treatment-100619275","NCT07342504","Better Experiences in Substance Treatment: A Brief Alcohol-focused Intervention Tailored for Patients in Opioid Agonist Treatment","Better Experiences in Substance Treatment: A Brief Alcohol-Focused Intervention Tailored for Patients in Opioid Agonist Treatment","Project BEST","Inclusion Criteria for the RCT:\n\n* Participants must be taking prescribed buprenorphine for at least 2 weeks\n* Participants must be 18 years or older.\n* Meet DSM-5 criteria for alcohol use disorder (AUD)\n* Participants must report alcohol use ≥ 1 day\u002Fweek on average in the past 28 days\n* Participants must be able to read simple English\n\nExclusion Criteria:\n\n* Currently receiving formal alcohol use treatment.\n* Currently experiencing psychosis",{"count":520,"type":23},60,[26],"This study will help determine the feasibility and acceptability of a brief opioid-informed alcohol intervention in patients receiving prescribed buprenorphine for opioid use who are currently drinking alcohol. It will also provide initial information on whether the intervention improves outcomes related to alcohol use. The results of this proof-of-concept study will inform whether a future larger clinical trial is warranted.",[524,337,525,29],"Alcohol Use Disorder","Alcohol Use",[524,527,528,337,529,530,531],"Alcohol Use Disorder (AUD)","Cognitive Behavioral Therapy","Opioid Use Disorder (OUD)","Motivational Enhancement Therapy","Cognitive Behavior Therapy (CBT)","2026-06-05",{"date":534,"type":37},"2026-06-09",{"date":536,"type":37},"2026-03-24",{"date":80,"type":23},{"name":539,"class":44},"University of Notre Dame",{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":4,"eligibilityCriteria":546,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":547,"targetDuration":4,"studyType":24,"phases":549,"briefSummary":550,"conditions":551,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":45},"100636109","erector-spinae-block-versus-paravertebral-block-on-chronic-pain-after-mastectomy-100636109","NCT07561411","Erector Spinae Block Versus Paravertebral Block on Chronic Pain After Mastectomy","The Effect of Erector Spinae Block Versus Paravertebral Block on the Incidence of Chronic Pain After Mastectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult patients between 18 and 80 years old.\n* Scheduled to total mastectomy with or without axillary dissection\n* Willing to receive regional anesthesia in addition to GA\n* ASA classification 1-3\n\nExclusion Criteria:\n\n* Previous thoracic surgery with an incision of \\>2 cm\n* Patient's refusal\n* Allergy to local anesthetics\n* Pregnant women\n* Any contraindications to thoracic PVB, including intrathoracic infection, infection at the puncture site, cancer invasion of the puncture site, severe spinal deformity, history of spinal surgery, and severe coagulopathy; anticoagulants intake.\n* American Society of Anesthesiologists (ASA) classification of 4 or higher,\n* History of chronic pain or untreated clinical severe depression",{"count":548,"type":23},132,[26],"The goal of this clinical trial is to learn if the erector spinae block can reduce the incidence of chronic pain compared to the paravertebral block in adult patients undergoing total mastectomy. The study includes patients aged 18 to 80 years scheduled for mastectomy, with or without axillary dissection. The main questions it aims to answer are:\n\n* Does erector spinae block reduce the incidence of chronic pain at 3 months after mastectomy compared to paravertebral block?\n* Does erector spinae block affect postoperative outcomes such as opioid consumption at 48 hours, pain scores (in PACU, 24 and 48 hours), block performance time, and the incidence of complications, anxiety or depression, and pain intensity at 3 months?\n\nResearchers will compare patients receiving erector spinae block to those receiving paravertebral block to determine if erector spinae block provides equivalent or improved outcomes in terms of chronic pain and perioperative measures.\n\nParticipants will:\n\n* Be randomly assigned to receive either erector spinae block or paravertebral block prior to surgery\n* Undergo total mastectomy (with or without axillary dissection)\n* Have their pain assessed in the PACU and at 24 and 48 hours postoperatively\n* Have opioid consumption measured during the first 48 hours after surgery\n* Be followed up at 3 months to assess chronic pain, pain intensity, and psychological outcomes (anxiety or depression)",[552,553,554,29],"Mastectomy; Lymphedema","Chronic Pain","Regional Anesthesia Morbidity","2026-06-01",{"date":557,"type":37},"2026-06-02",{"date":559,"type":37},"2026-05-19",{"date":561,"type":23},"2028-05-01",{"name":563,"class":44},"American University of Beirut Medical Center",{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":569,"acronym":4,"eligibilityCriteria":570,"healthyVolunteers":17,"sex":92,"minAge":19,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":24,"phases":573,"briefSummary":574,"conditions":575,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":45},"100549454","phase-4-opioid-use-after-laparoscopic-salpingectomy-100549454","NCT06434233","Opioid Use After Laparoscopic Salpingectomy","A Randomized Control Trial for Opioid Use After Laparoscopic Salpingectomy","Inclusion Criteria:\n\n* Individuals with a fallopian tube (unilateral and\u002For bilateral)\n* Age 18 years old and above\n* Undergoing minimally invasive (laparoscopic or robotic) unilateral or bilateral salpingectomy or other tubal sterilization procedure as the primary procedure\n* Benign indications for salpingectomy\u002Ftubal sterilization\n* Agreeing to participate\n\nExclusion Criteria:\n\n* Chronic pain syndromes patients including fibromyalgia\n* Patients currently on long-term (i.e. for more than three months) opioid use\n* Conversion to laparotomy\n* Allergy or other contraindication to the prescribed medications such as acetaminophen or oxycodone\n* Salpingectomy that occurs in conjunction with a major Gyn surgery (i.e. hysterectomy, etc)\n* Salpingectomy performed for treatment of ectopic pregnancy\n* Patients with a history of gastritis and\u002For GI bleeding",{"count":572,"type":23},38,[486],"The purpose of this study is to evaluate patient-reported post-operative pain scores following minimally invasive tubal sterilization procedures to determine if a multimodal, non-opioid pain control regimen is non-inferior to a pain control regimen including opioids.\n\nThe study team hypothesizes that with extensive counseling on pain management, multimodal medication use, and expectation with non-opioid methods can effectively eliminate the need for opioid prescriptions after laparoscopic salpingectomy.",[29,364,576],"Sterility, Female",{"date":578,"type":37},"2026-06-03",{"date":580,"type":37},"2024-04-25",{"date":582,"type":23},"2026-11",{"name":584,"class":44},"Johns Hopkins University",{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":590,"acronym":591,"eligibilityCriteria":592,"healthyVolunteers":17,"sex":92,"minAge":19,"maxAge":4,"enrollmentInfo":593,"targetDuration":4,"studyType":24,"phases":594,"briefSummary":595,"conditions":596,"keywords":597,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":607,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":611,"locationsCount":45},"100508822","neuroimaging-of-opioid-phase-opal-100508822","NCT05905419","Neuroimaging of Opioid Phase (OPAL)","Neurobiological Consequences of Long-Term Opioid Therapy in the Brain and Spinal Cord","OPAL","Inclusion Criteria for Healthy Controls:\n\n1. female and ages 18+\n2. ability to read\u002Funderstand English and give consent to participate\n3. no current or history of chronic pain\n4. not regularly taking any pain-relieving or mood-altering medications (per PI discretion)\n5. absence of use of opioid medications\n\nInclusion Criteria for Individuals with Chronic Pain:\n\n1. female and ages 18 +\n2. ability to read\u002Funderstand English and give consent to participate\n3. self-reported or physician diagnosis of fibromyalgia and\u002For chronic pain\n4. current use of opioid medication(s) for inclusion in the opioid patient group -OR- absence of use of opioid medications for inclusion in the non-opioid patient group\n\nExclusion Criteria (for both groups):\n\n1. limited ability to participate fully in behavioral tasks, longitudinal follow-up\n2. MRI contraindication\n3. any factors that at the discretion of the investigators would adversely affect the participant or the integrity of the study\n4. male",{"count":312,"type":23},[26],"The purpose of this study is to compare activity in the brains of female adults with chronic pain and\u002For opioid use, and healthy female adults that may help to develop new and targeted treatments for adults with chronic pain and alternatives to opioid therapy.",[553,29],[598,599,600,601,602,603,604,605,606],"fibromyalgia","women","brain","functional MRI","opioid","opiate","narcotic","chronic pain","pain",{"date":578,"type":37},{"date":609,"type":37},"2023-06-01",{"date":227,"type":23},{"name":612,"class":44},"Duke University",{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":618,"acronym":4,"eligibilityCriteria":619,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":620,"targetDuration":4,"studyType":140,"phases":4,"briefSummary":622,"conditions":623,"keywords":626,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":632,"startDateStruct":634,"completionDateStruct":636,"leadSponsor":638,"locationsCount":45},"100551965","understanding-the-acute-pain-phenotype-in-patients-undergoing-surgery-100551965","NCT06466941","Understanding the Acute Pain Phenotype in Patients Undergoing Surgery","Impact of Patient Phenotypic Features on the Experience and Effectiveness of Regional Anesthesia and Postoperative Pain","Inclusion Criteria:\n\n* Age ≥ 18\n* English speaking\n* Surgical or procedural patient who will be admitted postoperatively\n* Willingness to answer psychosocial survey and\u002For audio recorded semi-structured interview\n\nExclusion Criteria:\n\n-Cognitive dysfunction that precludes communication",{"count":621,"type":23},1000,"The goal of this observational study is to learn about how regional anesthesia (numbing medication) affects pain in patients with different psychosocial phenotypes such as different levels of concern about pain, sleep issues, and anxiety, who are having surgery.\n\nThe main questions are:\n\n1. Do psychosocial factors such as concerns about pain, sleep, anxiety affect the effectiveness of regional anesthesia?\n2. Do psychosocial factors and regional anesthesia affect the amount of opioids used after surgery?\n3. Do psychosocial factors and regional anesthesia affect development of chronic postsurgical pain?",[624,625,29],"Acute Pain","Chronic Post Operative Pain",[627,628,629,630],"regional anesthesia","peripheral nerve blocks","psychosocial phenotype","pain catastrophizing","2026-05-20",{"date":633,"type":37},"2026-05-22",{"date":635,"type":37},"2024-07-03",{"date":637,"type":23},"2028-12-31",{"name":255,"class":44}]